Literature DB >> 19186196

Rough mutants defective in core and O-polysaccharide synthesis and export induce antibodies reacting in an indirect ELISA with smooth lipopolysaccharide and are less effective than Rev 1 vaccine against Brucella melitensis infection of sheep.

María B Barrio1, María J Grilló, Pilar M Muñoz, Isabelle Jacques, David González, María J de Miguel, Clara M Marín, Montserrat Barberán, Jean-J Letesson, Jean-P Gorvel, Ignacio Moriyón, José M Blasco, Michel S Zygmunt.   

Abstract

Classical brucellosis vaccines induce antibodies to the O-polysaccharide section of the lipopolysaccharide that interfere in serodiagnosis. Brucella rough (R) mutants lack the O-polysaccharide but their usefulness as vaccines is controversial. Here, Brucella melitensis R mutants in all main lipopolysaccharide biosynthetic pathways were evaluated in sheep in comparison with the reference B. melitensis Rev 1 vaccine. In a first experiment, these mutants were tested for ability to induce anti-O-polysaccharide antibodies, persistence and spread through target organs, and innocuousness. Using the data obtained and those of genetic studies, three candidates were selected and tested for efficacy as vaccines against a challenge infecting 100% of unvaccinated ewes. Protection by R vaccines was 54% or less whereas Rev 1 afforded 100% protection. One-third of R mutant vaccinated ewes became positive in an enzyme-linked immunosorbent assay with smooth lipopolysaccharide due to the core epitopes remaining in the mutated lipopolysaccharide. We conclude that R vaccines interfere in lipopolysaccharide immunosorbent assays and are less effective than Rev 1 against B. melitensis infection of sheep.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19186196     DOI: 10.1016/j.vaccine.2009.01.025

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

1.  Development of a selective culture medium for primary isolation of the main Brucella species.

Authors:  M J De Miguel; C M Marín; P M Muñoz; L Dieste; M J Grilló; J M Blasco
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

2.  In vivo differences in the virulence, pathogenicity, and induced protective immunity of wboA mutants from genetically different parent Brucella spp.

Authors:  Zhen Wang; Jianrui Niu; Shuangshan Wang; Yanli Lv; Qingmin Wu
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

3.  Isolation of Brucella melitensis from a RB51-vaccinated seronegative goat.

Authors:  Enrique Herrera; Aldo Rivera; E Gabriela Palomares; Rigoberto Hernández-Castro; Efrén Díaz-Aparicio
Journal:  Trop Anim Health Prod       Date:  2011-04-01       Impact factor: 1.559

Review 4.  Brucellosis: the case for live, attenuated vaccines.

Authors:  Thomas A Ficht; Melissa M Kahl-McDonagh; Angela M Arenas-Gamboa; Allison C Rice-Ficht
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

5.  Limitations of the BP26 protein-based indirect enzyme-linked immunosorbent assay for diagnosis of Brucellosis.

Authors:  Ting Xin; Hongjun Yang; Nan Wang; Fang Wang; Peng Zhao; Haiguang Wang; Kairong Mao; Hongfei Zhu; Jiabo Ding
Journal:  Clin Vaccine Immunol       Date:  2013-07-17

6.  Progress in Brucella vaccine development.

Authors:  Xinghong Yang; Jerod A Skyberg; Ling Cao; Beata Clapp; Theresa Thornburg; David W Pascual
Journal:  Front Biol (Beijing)       Date:  2013-02-01

Review 7.  What have we learned from brucellosis in the mouse model?

Authors:  María-Jesús Grilló; José María Blasco; Jean Pierre Gorvel; Ignacio Moriyón; Edgardo Moreno
Journal:  Vet Res       Date:  2012-04-13       Impact factor: 3.683

Review 8.  Retrospective and prospective perspectives on zoonotic brucellosis.

Authors:  Edgardo Moreno
Journal:  Front Microbiol       Date:  2014-05-13       Impact factor: 5.640

9.  Deletion of the GI-2 integrase and the wbkA flanking transposase improves the stability of Brucella melitensis Rev 1 vaccine.

Authors:  Marcos Mancilla; María-Jesús Grilló; María-Jesús de Miguel; Ignacio López-Goñi; Beatriz San-Román; Ana Zabalza-Baranguá; Ignacio Moriyón
Journal:  Vet Res       Date:  2013-10-31       Impact factor: 3.683

10.  Evaluation in mice of Brucella ovis attenuated mutants for use as live vaccines against B. ovis infection.

Authors:  Pilar Sancho; Carmen Tejedor; Rebeca S Sidhu-Muñoz; Luis Fernández-Lago; Nieves Vizcaíno
Journal:  Vet Res       Date:  2014-06-04       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.